Location
United States, North America
Check Size
$100K - $10M
Investment Stage
Series A
Focus Areas
BioTech
Pharmaceuticals
About Investor
Chris Garabedian is the CEO of Xontogeny and Portfolio Manager at Perceptive Advisors’ PXV Fund, specializing in life sciences. He invests between $100K and $10.0M, with a focus on biotech and pharmaceuticals at Series A stage. Based between New York City and Boston, he brings decades of experience as a biotech executive and investor.
Previous investments
PolyCore Therapeutics
2022
VivoSense
25M |2022
Zucara Therapeutics
20M |2024
21M |2020
Similar Investors
AL
Abdul Ly
United States, North America
$1M - $4M
Seed
,Series A
,PS
Paul Straub
United States, North America
$100K - $2M
Pre Seed
,Seed
,RF
Riley Florsheim
United States, North America
$100K - $5M
Pre Seed
,Seed
,DG
Danielle Graham
Canada, North America
$100K - $300K
Pre Seed
,Seed
,JR
JJ Richa
United States, North America
$50K - $1M
Pre Seed
,Seed
,AL
Alicia Lenis
Canada, North America
$500K - $2M
Pre Seed
,Seed
,Is this You?
Is this you? Have any edits?
Fill out our update request form and we'll update ASAP